A recent study suggests that the use of 40,000 units weekly of recombinant human erythropoietin (EPO) in critically ill patients reduces the need for allogeneic blood transfusions (1). Patients who were randomized to receive EPO were less likely to undergo a transfusion than those who received placebo (50.5% vs. 60.4%, respectively 
in morbidity and mortality measures (although the study was not powered to detect such differences). Despite the lack of clinical findings, the authors emphasized the direct benefit of reducing the number of transfusions, in terms of a decrease in transfusion-associated adverse events. However, with the advent of better screening techniques, the incidence of transfusion-related infections has been greatly reduced in the past decade (2) (3) (4) .
The primary reasons to restrict blood transfusions are to protect blood as a scarce resource and to avoid known and unknown transfusion-related adverse events. However, the costs associated with reducing transfusions by substituting treatment with EPO are unknown. To answer this question, a formal analysis of the costs and risks associated with using EPO to reduce transfusions is required (1) . The purpose of this study was to assess the number needed to treat (NNT) and the incremental cost required to avoid one transfusion-related adverse event or death by using EPO.
MATERIALS AND METHODS
There were no human subjects associated with our study and, therefore, it is not subject to federal regulations regarding protection of human subjects. We conducted a series of NNT analyses based solely on data collected from previously published sources.
For the primary analysis, we estimated transfusion-related adverse event rates for which there is general consensus regarding the causal nature and for which there are incidence rate data in the peer-reviewed literature. The risks associated with a blood transfusion were quantified using the most recently available published evidence. A PubMed search with MESH headings was conducted to obtain literature regarding various risks of transfusion. This search used the following terms: blood transfusion, hepatitis B, hepatitis C, human immunodeficiency virus, human T-cell lymphotropic virus, errors, hemolytic reactions, contamination, immunodeficiency, wound infection, acute lung injury, and febrile reactions.
Our base analysis was repeated for each of three categories of adverse events: all known transfusion-related adverse events, serious transfusion-related adverse events, and transfusion-related adverse events that are likely fatal. These are not mutually exclusive categories; however, they represent distinct clinical groupings that deserve separate analysis. An adverse event was considered serious if it was associated with symptomatic acute hemolytic reaction, prolonged intubation lasting Ͼ7 days associated with transfusion-related acute lung injury (TRALI), development of a chronic viral disease, receipt of a bacterially contaminated unit of blood, or mortality. All viral and bacterial infections were considered likely fatal. Additionally, fatality rates for cases of TRALI and acute hemolytic reaction were assigned based on recent surveillance data (4 -6) .
Using estimates from a recent randomized controlled trial, we calculated the absolute risk of an adverse event per course of therapy by multiplying the risk per transfusion by the mean number of transfusions in patients receiving EPO (2.4) and not receiving EPO (3.0), respectively (1). The absolute risk reduction associated with EPO was calculated by taking the difference between the absolute risk per course of therapy with EPO and the absolute risk without EPO. The NNT with EPO to avoid one serious transfusion-related adverse event was calculated by taking the inverse of the absolute risk reduction when using EPO.
Cost calculations were conducted using the following assumptions: the mean number of doses for patients receiving EPO is 2.56; the cost of a 40,000 unit dose of EPO, in 2004 U.S. dollars, is $420; and the cost of a one unit blood transfusion is $315 (1) . The cost of EPO to avoid one transfusion-related adverse event was calculated by multiplying the NNT by the mean number of EPO doses and by the cost per EPO dose ( Table 1) . The cost savings generated by EPO via a reduction in blood transfusions was accounted for in the total cost to avoid a transfusion-related adverse event calculation. Total cost to avoid a transfusionrelated adverse event was calculated by summing the cost of EPO and the cost of transfusions for all patients. The incremental total cost of using EPO to avoid an adverse event was calculated as the difference between the EPO and non-EPO groups in the total cost (7, 8) . The total cost to avoid one transfusionrelated adverse event was calculated by multiplying the incremental total cost per patient of using EPO by the NNT to avoid one transfusion-related adverse event. All cost estimates are expressed in 2004 U.S. dollars.
Sensitivity Analyses. To assess the robustness of our calculations to variation in model estimates, we performed a series of sensitivity analyses. First, to assess the impact of variation in known and quantified risks of transfusion, we used the upper and lower bounds of the 95% confidence intervals of the risk of these events as initial variables for sensitivity analysis. The upper and lower sensitivity values for risk were established by simultaneously setting all risk estimates to the upper and lower bounds of their 95% confidence interval, respectively.
The impact of potential adverse events, or events that do not have a strong causal link established and/or no reasonable estimation of incidence can be made (e.g., bacterial infection, immunosuppression, and late-onset malignancies), were assessed in separate sensitivity analyses. For these analyses, the upper bounds of the 95% confidence interval for known risks were first doubled and then quadrupled.
To assess the impact of a potential doseresponse relationship between EPO and the requirement for blood transfusions, data from a previous randomized trial in which there was greater EPO use and greater reduction in transfusions were used (9) . In this study, patients received on average 190,000 units of EPO (1.9 times the amount in our base case assessment) and experienced a 45.6% reduction in units of blood transfused.
RESULTS
Risk Estimates. The prevalence of TRALI has been estimated to be 0.02% Table 1 per unit transfused (5, 6, 10) . Of these TRALI cases, approximately 20% (40 per million transfusions) result in a serious adverse event, including hypoxemia and pulmonary infiltrates that persist for Ն7 days (5, 6) . Mortality estimates due to TRALI range from approximately one per 3 million to ten per 1 million transfusions (4, 6) . The more conservative one per 3 million mortality rate was used for mortality calculations in this study.
Transfusion-related errors that result in ABO-incompatible blood administration can cause an acute hemolytic reaction, a potentially fatal reaction (10 -12) . A recent study of transfusion errors in New York State estimated the frequency of all errors to be one in 14,000 units transfused (11) . Many of these errors did not result in adverse events, for example, errors resulting from ABO-compatible units. The rate of symptomatic acute hemolytic reaction, the rate used for serious event calculations, was 101 per 9,000,000 units transfused (13 per million). The most recent evidence regarding mortality associated with receipt of ABO-incompatible blood suggests a rate of 1 per 1,700,000 units (4). Delayed hemolytic reactions probably occur more frequently but have less severe clinical sequelae (13) .
The risk of viral transmission was estimated based on a recent incidence and prevalence study of Red Cross blood donors (2). This study also used Schrieber and colleagues' (14) method to define residual infection risk attributable to window period infections, allowing calculation of 95% confidence intervals around infection rates. The estimated risk of human immunodeficiency virus (HIV) infection was calculated as 0.7 per million units. The incidences of hepatitis B virus and hepatitis C virus were estimated to be 4.9 and 3.6 per million units, respectively. The risk of human T-cell lymphotropic virus was estimated to be 0.3 per million red blood cell units. All viral infections were considered serious and potentially fatal.
The incidence of transfusion-transmitted bacterial infections was estimated from a recent study based on a prospective reporting system created by the American Red Cross, the Centers for Disease Control, and the Department of Defense (15) . From 1998 through 2000, five confirmed cases of transfusion-transmitted bacterial infection occurred from a total of 23,711,169 units transfused (0.2 cases per million units).
To calculate the risk of all, serious, and likely fatal adverse events, we summed these incidence estimates ( Table  2 ). The estimated combined risk of transfusion-related adverse events for the three risk strata in our study were as follows: 318 transfusion-related adverse events per million transfusions, 58 serious events per million transfusions, and 21 likely fatal events per million transfusions.
Absolute Risk Reduction, NNT, and Cost. Assuming transfusion rates of 2.4 for patients treated with EPO and three per patient with no EPO treatment (1), two patients need to be treated with EPO to avoid one blood transfusion at a cost of $2,154.
The absolute risk of any transfusionrelated adverse event per course of therapy for patients receiving EPO was estimated to be 762 per million, compared with 953 per million courses of therapy for those not receiving EPO (Table 3) . Therefore, the absolute risk reduction for all adverse events associated with EPO therapy was estimated to be 191 per million courses of therapy. The NNT to avoid one transfusion-related adverse event was 5,246. The cost of EPO to avoid one
The risk of a serious transfusionrelated adverse event per course of therapy was estimated to be 139 per million for EPO-treated patients and 174 per million for those without EPO treatment (Table 3) Table 3 ). The absolute risk reduction of using EPO for likely fatal events is 12 per million courses of therapy, resulting in an NNT of approximately 81,000. The cost of EPO to avoid a likely fatal event was $87,135,275; and the net cost accounting for reduced transfusions was $71,818,285.
Sensitivity Analyses. Complete results from all sensitivity analyses can be found in Table 4 . When we used the lower and upper bounds of the 95% confidence intervals for risk estimates, the NNT and cost to avoid a serious adverse event ranged from approximately 16,762 to 67,833 and $14.9 million to $60.2 million, respectively. The NNT and cost to avoid a likely fatal event ranged from 34,875 to 1,089,325 and $31 million to $968 million, respectively.
When we accounted for unknown or unquantified risks by quadrupling the upper bound of the risk estimate, the NNT was Ն4,188 for serious adverse events and 8,726 for likely fatal events. Costs associated with these estimates were $3.7 million for serious events and $7.7 million for likely fatal events. The relationship between absolute risk reduction by using EPO, which is dependent on the risk of a transfusion, and NNT and total cost is summarized in Figure 1 . Using EPO dosing and response from a previous randomized trial (9), approximately 10,000 patients would need to be treated with EPO at a cost of $14.5 million to avoid a serious adverse event. Approximately 28,000 would need to be treated at a cost of $40.8 million to avoid a likely fatal adverse event.
DISCUSSION
The main finding of our analysis was that 5,246 patients need to be treated at our institution at a cost approaching $5,000,000 to avoid one transfusionrelated adverse event as a result of EPO therapy. These findings were magnified greatly when the outcome of interest was avoiding a serious or likely fatal transfusion-related adverse event; Ͼ25,000 patients need to be treated at costs exceeding $25,000,000. Although the direction of the findings was expected, their magnitude was surprisingly large.
The growing cost of pharmaceuticals puts financial pressure on institutions and, therefore, increases the need for rational resource utilization. In an environment of unlimited resources, any intervention that provides a net benefit should be performed regardless of the cost. However, resources are constrained in reality, and therefore the efficiency whereby they are expended must be explicitly considered to optimally deploy the resources. Expenditures become more efficient as greater benefit is derived from them. Although the study conducted by Corwin and colleagues (1) showed a reduction in number of transfusions when using EPO, there was no significant difference in morbidity or mortality outcomes between treatment groups. Our analysis provides a gauge of efficiency by explicitly calculating costs and, in terms of transfusionrelated adverse events avoided, of using EPO in the critically ill.
The formal quantification of the costs associated with reducing the risk of blood transfusions in our analysis gives important context to the expectation of "zerorisk" transfusions. This expectation of zero-risk has driven the search for better, yet more costly, interventions (16, 17) . However, some have questioned the efficiency of paying for further gains in the safety of the blood supply, given the current low level of risk (16 -20) . When the cost-effectiveness of interventions to improve blood safety has been formally assessed, they have not been found costeffective compared with other commonly used medical interventions (3, (21) (22) (23) . One author has even questioned the appropriateness of using a prevented transfusion as an outcome measure, while suggesting that improved morbidity and mortality are more appropriate measures (17) . This situation is not unlike the famed sixth stool guaiac example, which demonstrated that the law of diminishing returns has a surprisingly large economic impact for medical interventions (24) . In this example, the cost of identifying an additional case of cancer became exponentially more expensive when, according to American Cancer Society guidelines, up to six sequential guaiac stool tests were conducted. To find one case of cancer in patients who had five negative tests cost Ͼ$132,000,000 (2004 U.S. dollars). The American Cancer Society changed their recommendation after this article was published. Likewise, we believe that although zero-risk transfusions is optimal in principle, the economic inefficiency of reaching this goal cannot be ignored. In the absence of morbidity or mortality benefit of EPO in this population, greater overall patient benefit could be realized by redeploying resources elsewhere. Future efforts should attempt to identify populations that may derive maximal benefit from EPO therapy. A recent abstract suggested that long-term critically ill patients experience a 50% reduction in the total number of units transfused when treated with 40,000 units EPO weekly compared with placebo (40 vs. 85) (25) . Additionally, there was a nonstatistically significant improvement in mortality in patients treated with EPO. This preliminary evidence suggests that EPO may have a greater benefit in the longterm critically ill. If the increased effect maintains durability in larger studies, the challenge will shift to identifying critically ill patients who will require a longterm stay. Although it has been shown that clinicians can predict who will stay 3 days quite routinely, this is difficult to predict on admission for longer term patients who may stay in the ICU for months (26) . Other populations that are reasonable candidates for EPO therapy include patients with either acute or chronic renal failure on renal replacement therapy, for whom EPO has become the standard of care. Patients who are Jehovah's Witnesses may also benefit by using EPO to help maintain higher hemoglobin levels that would obviate the need for transfusion. We also encourage a multiple-prong approach to the reduction of risk from transfusion that includes adhering to a transfusion threshold such as suggested by Hebert et al. (27) and reduction in blood waste and lab draws.
Our analysis has several limitations. Although accounting for all potential adverse events would be ideal, sufficient data regarding the incidence of potential adverse events, such as transfusionrelated immunomodulation, infection, and cancer recurrence, are not available. Therefore, our base analysis does not consider the impact of these potential events. To best account for these potential effects, we conducted sensitivity analyses that increased the incidence of transfusion-related adverse events up to four times the upper limit of the 95% confidence interval of known adverse events. As new data become available regarding these potential adverse events, this analysis should be repeated. Nevertheless, our study is based on the best available evidence, which is indeterminate regarding the presence and incidence of these potential adverse events (28 -41) .
Our analysis did not compare EPO to other blood safety interventions, such as universal leukoreduction and improved HIV and hepatitis C virus testing. The cost and effect of these interventions relative to EPO have not been formally assessed. However, such comparisons assess the value of these interventions relative to each other and not the more basic question of their worth compared with doing nothing. For example, if intervention A is cost-effective compared with intervention B, it could still be the case that neither is an efficient use of resources. In any case, such comparisons of relative value are beyond the scope of this article and do not affect the results contained herein.
Our study did not account for the fact that blood is a limited resource and as such conservation is a worthwhile goal. Although this is indisputable, the economic value of this precious resource above and beyond acquisition cost is difficult to quantify. We also recognize that our analysis does not include other interventions that may reduce the risk of transfusions, such as leukoreduction and advanced blood screening procedures. The results of the current analysis may be put in a new context as data become available regarding the costs and effectiveness of these interventions and how they interact with EPO treatment to further reduce risk. Evidence has emerged recently that new pathogens such as the West Nile virus may be transmitted via blood products (42) (43) (44) . The transmission of West Nile virus is highly variable based on geography and time of year. Therefore, we were unable to quantify a useful risk estimate for West Nile virus transmission. However, the sensitivity analyses cover the range of transmission, morbidity, and mortality reported in the literature. Our analysis did not account for the societal cost of transfusion-related adverse events. Nevertheless, it is unlikely that any adverse event, including death, would be valued as high as the cost to avoid one adverse event in our analysis. For example, a recent study of HIV infection estimated the total lifetime cost for a newly infected patient to be approximately $270,000 (2004 U.S. dollars, adjusted using medical care services component of the Consumer Price Index) (14) . As data regarding societal costs and effectiveness become available, a formal assessment of the cost-effectiveness of using EPO should be conducted. Finally, our study is highly reliant on data from one randomized trial.
CONCLUSIONS
From the perspective of avoidance of transfusion-related adverse events, the use of EPO to reduce the need for blood transfusion in critically ill patients is associated with a high NNT and cost to avoid one transfusion-related adverse event and, as such, its routine use for this purpose is not recommended. (45) 
